Recruiting

IlluminOss

Sponsor:

IlluminOss Medical, Inc.

Code:

NCT05206981

Conditions

Traumatic Fracture

Pathological Fracture

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

IlluminOss Device

Study Details

Brief summary:

This is a multi-center, observational patient registry. The primary objective of the study is to collect safety and performance data on the IlluminOss Device when used to provide stabilization and alignment for the treatment of traumatic or impending and pathologic fractures.

Conditions

Traumatic Fracture

Pathological Fracture

Study ID

NCT05206981

Start date

Jun 11, 2021

Status verified date

Apr, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient has been deemed a candidate for the IlluminOss device
2. Patient is male or non-pregnant female
3. Patient is willing and able to comply with the postoperative scheduled clinical and radiographic evaluations
4. Patient is willing and able to give informed consent if required
5. Traumatic patient is over the age of 50
6. IlluminOss procedure is the initial procedure to treat the traumatic injury

Exclusion Criteria:

United States (U.S.)

This product is contraindicated in U.S. patients who have:

1. an active or incompletely treated infection that could involve the site where the device will be implanted;
2. are allergic to any of the implant materials or to dental glue;
3. have an intramedullary canal measuring smaller than the diameter of the delivery sheath provided at the site of the fracture;
4. distant foci of infections which may spread to the implant site, have open fractures with severe contamination;
5. or in patients for whom delivery sheath is unable to cross fracture site after proper fracture reduction and realignment.

European Union (EU)

This product is contraindicated in EU patients who have:

For all Bones:

1. Patients who are considered skeletally immature.
2. Presence of active or incompletely treated infections that could involve the site where the device will be implanted.
3. Patients allergic to any of the implant materials, or to dental glue.
4. Patients whose intramedullary canal at site of fracture measures smaller than the diameter of the sheath provided.
5. Uncooperative patient or patient with neurologic disorder, incapable of following directions.
6. Distant foci of infections which may spread to the implant site.
7. Vascular insufficiency.
8. Open fractures with severe contamination.
9. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable.
10. Delivery sheath is unable to cross fracture site after proper fracture reduction and realignment.

For acute Humerus fractures:
11. Patients who are under the age of Fifty (50)

For all bones excluding pathologic Humerus:
12. Metabolic disorders which may impair bone formation.
13. Osteomalacia.
14. Vascular insufficiency, muscular atrophy, or neuro-muscular disease.

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Interventions

IlluminOss Device

Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.

Primary outcome measure

  • Composite Safety Success Rate [ Time Frame: 12 Months ]

Central Contacts and Locations

Central contacts

Locations

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Principal Investigator:

Charles Moon, MD

Presbyterian St Luke's Medical Ctr

Recruiting

Denver, Colorado, United States, 80218

Contacts

Principal Investigator:

Daniel Lerman, MD

University of Miami Hospital

Recruiting

Miami, Florida, United States, 33136

Contacts

Anastasiya Drandarov

axd1361@med.miami.edu

Principal Investigator:

Brooke Crawford, MD

Weston Outpatient Surgical Center

Recruiting

Weston, Florida, United States, 33326

Principal Investigator:

David Shenassa, MD

Jacobi Medical Center

Recruiting

The Bronx, New York, United States, 10461

Contacts

Principal Investigator:

Milan Sen, MD

Wake Forest Baptist Health

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

Principal Investigator:

Cynthia Emory, MD

Temple University Hospital

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Contacts

Principal Investigator:

Theresa Pazionis

University of Pittsburgh Medical Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contacts

Beata Krawczyk

krawbx@UPMC.EDU

Principal Investigator:

Richard McGough, MD

Ortho Rhode Island

Recruiting

Wakefield, Rhode Island, United States, 02879

Contacts

Principal Investigator:

Michael Bradley, MD

Memorial Hermann Hospital

Recruiting

Katy, Texas, United States, 77494

Contacts

Principal Investigator:

William Harvin, MD

More Information

Sponsor

IlluminOss Medical, Inc.

Last update posted

Apr 17, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by IlluminOss Medical, Inc. on 2026-04-17.